{"PubmedArticle":{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM","IndexingMethod":"Manual"},"PMID":{"@attributes":{"Version":"1"},"@text":"26215877"},"DateCompleted":{"Year":"2015","Month":"11","Day":"02"},"DateRevised":{"Year":"2023","Month":"12","Day":"01"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":{"@attributes":{"IssnType":"Electronic"},"@text":"1526-632X"},"JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"85","Issue":"4","PubDate":{"Year":"2015","Month":"Jul","Day":"28"}},"Title":"Neurology","ISOAbbreviation":"Neurology"},"ArticleTitle":"Evidence-based guideline summary: Evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine.","Pagination":{"StartPage":"357","EndPage":"364","MedlinePgn":"357-64"},"ELocationID":[{"@attributes":{"EIdType":"doi","ValidYN":"Y"},"@text":"10.1212\/WNL.0000000000001783"}],"Abstract":{"AbstractText":[{"@attributes":{"Label":"OBJECTIVE","NlmCategory":"OBJECTIVE"},"@text":"To develop recommendations for the evaluation, diagnosis, prognostication, and treatment of facioscapulohumeral muscular dystrophy (FSHD) from a systematic review and analysis of the evidence."},{"@attributes":{"Label":"METHODS","NlmCategory":"METHODS"},"@text":"Relevant articles were analyzed in accordance with the American Academy of Neurology classification of evidence schemes for diagnostic, prognostic, and treatment studies. Recommendations were linked to the strength of the evidence and other factors."},{"@attributes":{"Label":"RESULTS AND RECOMMENDATIONS","NlmCategory":"CONCLUSIONS"},"@text":"Available genetic testing for FSHD type 1 is highly sensitive and specific. Although respiratory insufficiency occurs rarely in FSHD, patients with severe FSHD should have routine pulmonary function testing. Routine cardiac screening is not necessary in patients with FSHD without cardiac symptoms. Symptomatic retinal vascular disease is very rare in FSHD. Exudative retinopathy, however, is potentially preventable, and patients with large deletions should be screened through dilated indirect ophthalmoscopy. The prevalence of clinically relevant hearing loss is not clear. In clinical practice, patients with childhood-onset FSHD may have significant hearing loss. Because undetected hearing loss may impair language development, screening through audiometry is recommended for such patients. Musculoskeletal pain is common in FSHD and treating physicians should routinely inquire about pain. There is at present no effective pharmacologic intervention in FSHD. Available studies suggest that scapular fixation is safe and effective. Surgical scapular fixation might be cautiously offered to selected patients. Aerobic exercise in FSHD appears to be safe and potentially beneficial. On the basis of the evidence, patients with FSHD might be encouraged to engage in low-intensity aerobic exercises."}],"CopyrightInformation":"\u00a9 2015 American Academy of Neurology."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Tawil","ForeName":"Rabi","Initials":"R","AffiliationInfo":[{"Affiliation":"From the MDA Neuromuscular Disease Clinic (R.T.) and the Department of Neurology (C.H., S.P.), School of Medicine and Dentistry, University of Rochester Medical Center, NY; the Department of Neurology (J.T.K.), Wexner Medical Center, Ohio State University, Columbus; the Department of Neurology (G.G.), University of Kansas School of Medicine, Kansas City; and the Department of Neurology (M.B.), Miller School of Medicine, University of Miami, OH."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Kissel","ForeName":"John T","Initials":"JT","AffiliationInfo":[{"Affiliation":"From the MDA Neuromuscular Disease Clinic (R.T.) and the Department of Neurology (C.H., S.P.), School of Medicine and Dentistry, University of Rochester Medical Center, NY; the Department of Neurology (J.T.K.), Wexner Medical Center, Ohio State University, Columbus; the Department of Neurology (G.G.), University of Kansas School of Medicine, Kansas City; and the Department of Neurology (M.B.), Miller School of Medicine, University of Miami, OH."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Heatwole","ForeName":"Chad","Initials":"C","AffiliationInfo":[{"Affiliation":"From the MDA Neuromuscular Disease Clinic (R.T.) and the Department of Neurology (C.H., S.P.), School of Medicine and Dentistry, University of Rochester Medical Center, NY; the Department of Neurology (J.T.K.), Wexner Medical Center, Ohio State University, Columbus; the Department of Neurology (G.G.), University of Kansas School of Medicine, Kansas City; and the Department of Neurology (M.B.), Miller School of Medicine, University of Miami, OH."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Pandya","ForeName":"Shree","Initials":"S","AffiliationInfo":[{"Affiliation":"From the MDA Neuromuscular Disease Clinic (R.T.) and the Department of Neurology (C.H., S.P.), School of Medicine and Dentistry, University of Rochester Medical Center, NY; the Department of Neurology (J.T.K.), Wexner Medical Center, Ohio State University, Columbus; the Department of Neurology (G.G.), University of Kansas School of Medicine, Kansas City; and the Department of Neurology (M.B.), Miller School of Medicine, University of Miami, OH."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Gronseth","ForeName":"Gary","Initials":"G","AffiliationInfo":[{"Affiliation":"From the MDA Neuromuscular Disease Clinic (R.T.) and the Department of Neurology (C.H., S.P.), School of Medicine and Dentistry, University of Rochester Medical Center, NY; the Department of Neurology (J.T.K.), Wexner Medical Center, Ohio State University, Columbus; the Department of Neurology (G.G.), University of Kansas School of Medicine, Kansas City; and the Department of Neurology (M.B.), Miller School of Medicine, University of Miami, OH."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Benatar","ForeName":"Michael","Initials":"M","AffiliationInfo":[{"Affiliation":"From the MDA Neuromuscular Disease Clinic (R.T.) and the Department of Neurology (C.H., S.P.), School of Medicine and Dentistry, University of Rochester Medical Center, NY; the Department of Neurology (J.T.K.), Wexner Medical Center, Ohio State University, Columbus; the Department of Neurology (G.G.), University of Kansas School of Medicine, Kansas City; and the Department of Neurology (M.B.), Miller School of Medicine, University of Miami, OH."}]},{"@attributes":{"ValidYN":"Y"},"CollectiveName":"Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology"},{"@attributes":{"ValidYN":"Y"},"CollectiveName":"Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine"}]},"Language":["eng"],"GrantList":{"@attributes":{"CompleteYN":"Y"},"Grant":[{"GrantID":"T32 NS007338","Acronym":"NS","Agency":"NINDS NIH HHS","Country":"United States"},{"GrantID":"DD10-1012","Acronym":"DD","Agency":"NCBDD CDC HHS","Country":"United States"}]},"PublicationTypeList":{"PublicationType":[{"@attributes":{"UI":"D016428"},"@text":"Journal Article"},{"@attributes":{"UI":"D017065"},"@text":"Practice Guideline"},{"@attributes":{"UI":"D013485"},"@text":"Research Support, Non-U.S. Gov't"},{"@attributes":{"UI":"D013487"},"@text":"Research Support, U.S. Gov't, P.H.S."}]}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Neurology","NlmUniqueID":"0401060","ISSNLinking":"0028-3878"},"CitationSubset":["IM"],"MeshHeadingList":{"MeshHeading":[{"DescriptorName":{"@attributes":{"UI":"D019468","MajorTopicYN":"Y"},"@text":"Disease Management"}},{"DescriptorName":{"@attributes":{"UI":"D006801","MajorTopicYN":"N"},"@text":"Humans"}},{"DescriptorName":{"@attributes":{"UI":"D020391","MajorTopicYN":"N"},"@text":"Muscular Dystrophy, Facioscapulohumeral"},"QualifierName":[{"@attributes":{"UI":"Q000175","MajorTopicYN":"Y"},"@text":"diagnosis"},{"@attributes":{"UI":"Q000628","MajorTopicYN":"Y"},"@text":"therapy"}]}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2015","Month":"7","Day":"29","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2015","Month":"7","Day":"29","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2015","Month":"11","Day":"3","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pmc-release"},"Year":"2016","Month":"7","Day":"28"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"26215877"},{"@attributes":{"IdType":"pmc"},"@text":"PMC4520817"},{"@attributes":{"IdType":"doi"},"@text":"10.1212\/WNL.0000000000001783"},{"@attributes":{"IdType":"pii"},"@text":"WNL.0000000000001783"}]},"ReferenceList":[{"Reference":[{"Citation":"Padberg GW. Facioscapulohumeral Disease. Leiden: University of Leiden; 1982."},{"Citation":"Flanigan KM, Coffeen CM, Sexton L, Stauffer D, Brunner S, Leppert MF. Genetic characterization of a large, historically significant Utah kindred with facioscapulohumeral dystrophy. Neuromuscul Disord 2001;11:525\u2013529.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"11525880"}]}},{"Citation":"Tawil R, Van Der Maarel SM. Facioscapulohumeral muscular dystrophy. Muscle Nerve 2006;34:1\u201315.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"16508966"}]}},{"Citation":"The FSH-DY Group. A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials. Neurology 1997;48:38\u201346.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"9008491"}]}},{"Citation":"St\u00fcbgen JP, Stipp A. Facioscapulohumeral muscular dystrophy: a prospective study of weakness and functional impairment. J Neurol 2010;257:1457\u20131464.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"20352247"}]}},{"Citation":"Wijmenga C, Brouwer OF, Padberg GW, Frants RR. Transmission of de-novo mutation associated with facioscapulohumeral muscular dystrophy. Lancet 1992;340:985\u2013986.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"1357400"}]}},{"Citation":"van Deutekom JC, Wijmenga C, van Tienhoven EA, et al. FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. Hum Mol Genet 1993;2:2037\u20132042.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"8111371"}]}},{"Citation":"Lemmers RJ, de Kievit P, Sandkuijl L, et al. Facioscapulohumeral muscular dystrophy is uniquely associated with one of the two variants of the 4q subtelomere. Nat Genet 2002;32:235\u2013236.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"12355084"}]}},{"Citation":"Gabriels J, Beckers MC, Ding H, et al. Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. Gene 1999;236:25\u201332.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"10433963"}]}},{"Citation":"Lyle R, Wright TJ, Clark LN, Hewitt JE. The FSHD-associated repeat, D4Z4, is a member of a dispersed family of homeobox-containing repeats, subsets of which are clustered on the short arms of the acrocentric chromosomes. Genomics 1995;28:389\u2013397.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"7490072"}]}},{"Citation":"Lemmers RJ, van der Vliet PJ, Klooster R, et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 2010;329:1650\u20131653.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pmc"},"@text":"PMC4677822"},{"@attributes":{"IdType":"pubmed"},"@text":"20724583"}]}},{"Citation":"Snider L, Geng LN, Lemmers RJ, et al. Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. PLoS Genet 2010;6:e1001181.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pmc"},"@text":"PMC2965761"},{"@attributes":{"IdType":"pubmed"},"@text":"21060811"}]}},{"Citation":"de Greef JC, Lemmers RJ, van Engelen BG, et al. Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD. Hum Mutat 2009;30:1449\u20131459.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"19728363"}]}},{"Citation":"de Greef JC, Lemmers RJ, Cama\u00f1o P, et al. Clinical features of facioscapulohumeral muscular dystrophy 2. Neurology 2010;75:1548\u20131554.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pmc"},"@text":"PMC2974464"},{"@attributes":{"IdType":"pubmed"},"@text":"20975055"}]}},{"Citation":"Lemmers RJ, Tawil R, Petek LM, et al. Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat Genet 2012;44:1370\u20131374.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pmc"},"@text":"PMC3671095"},{"@attributes":{"IdType":"pubmed"},"@text":"23143600"}]}},{"Citation":"Tawil R, van der Maarel SM, Tapscott SJ. Facioscapulohumeral dystrophy: the path to consensus on pathophysiology. Skelet Muscle 2014;4:12.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pmc"},"@text":"PMC4060068"},{"@attributes":{"IdType":"pubmed"},"@text":"24940479"}]}},{"Citation":"Tawil R, van der Maarel S, Padberg GW, van Engelen BG. 171st ENMC international workshop: Standards of care and management of facioscapulohumeral muscular dystrophy. Neuromuscul Disord 2010;20:471\u2013475.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"20554202"}]}},{"Citation":"Attarian S, Salort-Campana E, Nguyen K, Behin A, Andoni Urtizberea J. Recommendations for the management of facioscapulohumeral muscular dystrophy in 2011. Rev Neurol 2012;168:910\u2013918.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"22551571"}]}},{"Citation":"Narayanaswami P, Weiss M, Selcen D, et al. Evidence-based guideline summary: diagnosis and treatment of limb-girdle and distal dystrophies: report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. Neurology 2014;83:1453\u20131463.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pmc"},"@text":"PMC4206155"},{"@attributes":{"IdType":"pubmed"},"@text":"25313375"}]}},{"Citation":"Kang PB, Morrison L, Iannaccone ST, et al. Evidence-based guideline summary: evaluation, diagnosis, and management of congenital muscular dystrophy: report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. Neurology 2015;84:1369\u20131378.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pmc"},"@text":"PMC4388744"},{"@attributes":{"IdType":"pubmed"},"@text":"25825463"}]}},{"Citation":"Padberg GW, Lunt PW, Koch M, Fardeau M. Diagnostic criteria for facioscapulohumeral muscular dystrophy. Neuromuscul Disord 1991;1:231\u2013234.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"1822799"}]}},{"Citation":"American Academy of Neurology. Clinical Practice Guidelines Process Manual, 2004 ed\nSt. Paul, MN: The American Academy of Neurology; 2004. \nAvailable at: https:\/\/www.aan.com\/Guidelines\/Home\/Development. Accessed February 12, 2012."},{"Citation":"American Academy of Neurology. Clinical Practice Guidelines Process Manual, 2011 ed\nSt. Paul, MN: The American Academy of Neurology; 2011. \nAvailable at: https:\/\/www.aan.com\/Guidelines\/Home\/Development. Accessed February 12, 2012."},{"Citation":"Hsu YD, Kao MC, Shyu WC, et al. Application of chromosome 4q35-qter marker (pFR-1) for DNA rearrangement of facioscapulohumeral muscular dystrophy patients in Taiwan. J Neurol Sci 1997;149:73\u201379.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"9168169"}]}},{"Citation":"Funakoshi M, Goto K, Arahata K. Epilepsy and mental retardation in a subset of early onset 4q35-facioscapulohumeral muscular dystrophy. Neurology 1998;50:1791\u20131794.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"9633729"}]}},{"Citation":"Zeng Y, Zhang C, Su Q. Gene diagnosis of facioscapulohumeral muscular dystrophy [in Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2001;18:213\u2013215.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"11402453"}]}},{"Citation":"Goto K, Lee JH, Matsuda C, et al. DNA rearrangements in Japanese facioscapulohumeral muscular dystrophy patients: clinical correlations. Neuromuscul Disord 1995;5:201\u2013208.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"7633185"}]}},{"Citation":"Scionti I, Greco F, Ricci G, et al. Large-scale population analysis challenges the current criteria for the molecular diagnosis of fascioscapulohumeral muscular dystrophy. Am J Hum Genet 2012;90:628\u2013635.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pmc"},"@text":"PMC3322229"},{"@attributes":{"IdType":"pubmed"},"@text":"22482803"}]}},{"Citation":"Ricci E, Galluzzi G, Deidda G, et al. Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype. Ann Neurol 1999;45:751\u2013757.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"10360767"}]}},{"Citation":"Lemmers RJ, Wohlgemuth M, van der Gaag KJ, et al. Specific sequence variations within the 4q35 region are associated with facioscapulohumeral muscular dystrophy. Am J Hum Genet 2007;81:884\u2013894.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pmc"},"@text":"PMC2265642"},{"@attributes":{"IdType":"pubmed"},"@text":"17924332"}]}},{"Citation":"Spurlock G, Jim HP, Upadhyaya M. Confirmation that the specific SSLP microsatellite allele 4qA161 segregates with fascioscapulohumeral muscular dystrophy (FSHD) in a cohort of multiplex and simplex FSHD families. Muscle Nerve 2010;42:820\u2013821.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"20928905"}]}},{"Citation":"K\u00f6hler J, R\u00f6hrig D, Bathke KD, Koch MC. Evaluation of the facioscapulohumeral muscular dystrophy (FSHD1) phenotype in correlation to the concurrence of 4q35 and 10q26 fragments. Clin Genet 1999;55:88\u201394.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"10189085"}]}},{"Citation":"Statland JM, Tawil R. Risk of functional impairment in facioscapulohumeral muscular dystrophy. Muscle Nerve 2014;49:520\u2013527.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"23873337"}]}},{"Citation":"Lunt PW, Jardine PE, Koch M, et al. Phenotypic-genotypic correlation will assist genetic counseling in 4q35-facioscapulohumeral muscular dystrophy. Muscle Nerve Suppl 1995;S103\u2013S109.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"23573595"}]}},{"Citation":"Tawil R, Forrester J, Griggs RC, et al. Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy: The FSH-DY Group. Ann Neurol 1996;39:744\u2013748.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"8651646"}]}},{"Citation":"Sakellariou P, Kekou K, Fryssira H, et al. Mutation spectrum and phenotypic manifestation in FSHD Greek patients. Neuromuscul Disord 2012;22:339\u2013349.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"22357364"}]}},{"Citation":"Wohlgemuth M, van der Kooi EL, van Kesteren RG, van der Maarel SM, Padberg GW. Ventilatory support in facioscapulohumeral muscular dystrophy. Neurology 2004;63:176\u2013178.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"15249635"}]}},{"Citation":"Kilmer DD, Abresch RT, McCrory MA, et al. Profiles of neuromuscular diseases. Facioscapulohumeral muscular dystrophy. Am J Phys Med Rehabil 1995;74(5 suppl):S131\u2013S139.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"7576420"}]}},{"Citation":"de Visser M, de Voogt WG, la Rivi\u00e8re GV. The heart in Becker muscular dystrophy, facioscapulohumeral dystrophy, and Bethlem myopathy. Muscle Nerve 1992;15:591\u2013596.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"1584251"}]}},{"Citation":"Stevenson WG, Perloff JK, Weiss JN, Anderson TL. Facioscapulohumeral muscular dystrophy: evidence for selective, genetic electrophysiologic cardiac involvement. J Am Coll Cardiol 1990;15:292\u2013299.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"2299071"}]}}]}]}}}